A bill to prevent conflicts of interest that stem from the revolving door that raises concerns about the independence of pharmaceutical regulators.
The bill’s titles are written by its sponsor.
Sponsor and status
Sponsor. Senator for Wisconsin. Democrat.
Last Updated: Nov 1, 2017
Length: 17 pages
115th Congress, 2017–2019
This bill was introduced on November 1, 2017, in a previous session of Congress, but was not enacted.
Nov 1, 2017
Bills and resolutions are referred to committees which debate the bill before possibly sending it on to the whole chamber.
S. 2057 (115th) was a bill in the United States Congress.
A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.
This bill was introduced in the 115th Congress, which met from Jan 3, 2017 to Jan 3, 2019. Legislation not enacted by the end of a Congress is cleared from the books.
How to cite this information.
We recommend the following MLA-formatted citation when using the information you see here in academic work:
GovTrack.us. (2019). S. 2057 — 115th Congress: Pharmaceutical Regulation Conflict of Interest Act. Retrieved from https://www.govtrack.us/congress/bills/115/s2057
“S. 2057 — 115th Congress: Pharmaceutical Regulation Conflict of Interest Act.” www.GovTrack.us. 2017. June 16, 2019 <https://www.govtrack.us/congress/bills/115/s2057>
Pharmaceutical Regulation Conflict of Interest Act, S. 2057, 115th Cong. (2017).
|title=S. 2057 (115th)
|accessdate=June 16, 2019
|author=115th Congress (2017)
|date=November 1, 2017
|quote=Pharmaceutical Regulation Conflict of Interest Act
Where is this information from?
GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.